REVIEW

Intra-arterial treatment of patients with acute ischemic stroke and internal carotid artery occlusion: a literature review

Manon Kappelhof, 1 Henk A Marquering, 1,2 Olvert A Berkhemer, 1 Charles B L M Majoie 1

ABSTRACT

Introduction Acute ischemic stroke (AIS) due to internal carotid artery (ICA) occlusion has a poor prognosis if treated by intravenous thrombolysis. Intra-arterial (IA) treatment is a promising alternative. However, its effectiveness is still unproven.

Methods We collected all publications describing results of IA treatment in acute ICA occlusions. All studies with 10 patients or more providing data on clinical outcome were included. The results by occlusion site (intracranial, extracranial or tandem occlusions) and treatment method, using recanalization, symptomatic intracranial hemorrhage, mortality and favorable clinical outcome (defined as modified Rankin Scale score 0–2) as outcome measures.

Results 32 studies totaling 1107 patients were included. In the population with intracranial ICA occlusion, recanalization (69% vs 38%, p<0.001) and favorable outcome (34% vs 12%, p<0.001) rates were significantly higher for mechanical thrombectomy than IVT. In the population with extracranial ICA occlusion, stenting resulted in a higher recanalization rate (87% vs 48%, p<0.001) and favorable outcome rate (68% vs 15%, p<0.001) and lower mortality (18% vs 41%, p=0.048) than IA thrombolysis. In the tandem occlusion population, a statistically significant lower death rate was found for the group treated with IA thrombolysis only compared with the groups with any mechanical treatment of the intracranial occlusion (0% vs 34%, p=0.002 and 0% vs 33%, p=0.001).

Conclusions This review shows that, for patients with AIS due to an extracranial and/or intracranial ICA occlusion, stenting and mechanical thrombectomy are associated with higher recanalization rates and improved functional outcomes compared with IA thrombolysis.

INTRODUCTION

Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) is the most common treatment for acute ischemic stroke (AIS). However, results of this treatment are poor in patients with large vessel occlusions. 1, 2 Patients with AIS secondary to an internal carotid artery (ICA) occlusion have an especially poor prognosis. According to a recent study on treatment results for this patient group, there was no significant difference in recanalization or clinical outcome rates between IVT and placebo. 3 Other studies report that IVT of AIS due to ICA occlusions results in a death rate of 24–27% of patients. 4–6 In these studies, good clinical outcome, represented as a modified Rankin Scale (mRS) score of 0–2, occurred in only 10–29% of cases. 4–6 It has been suggested that intra-arterial (IA) treatment may be a better alternative for this specific patient population. A recent systematic review 7 suggests that the endovascular treatment of acute ICA occlusions results in improved clinical outcomes compared with IVT. However, endovascular treatment approaches are heterogeneous and may include IA thrombolysis (IAT), microwire clot disruption (MCD), angioplasty, thromboaspiration, stenting and thrombectomy with stent retrievers or MERCI retrievers.

In this review our aim was to compare the rates of recanalization, symptomatic intracranial hemorrhage (sICH), clinical outcome and mortality of mechanical therapy for intracranial ICA occlusion and stenting for extracranial ICA occlusion with IAT.

METHODS

The PubMed/Medline database was searched for data from January 1995 through June 2013. We used the search terms ‘stroke’, ‘carotid’, ‘occlusion’, ‘thrombolytic therapy’, ‘endovascular’ and their synonyms. For greater specificity, we divided this search into articles that were not (yet) indexed for Medline and articles that had already been indexed. This way we could use the filter ‘Humans’ on the latter search. A single observer (MK) reviewed all the articles that described the results of IA treatment of ICA occlusions. Only articles in English language were included. Case reports and articles that were not available online were excluded. All articles with fewer than 10 cases of endovascular treatment were excluded to minimize the chance of an anecdotal outcome. If a study also contained patients with an occlusion at a location other than the ICA, we only included the ICA occlusion cases. ICA occlusions caused by a dissection were excluded. We only included studies that reported clinical outcomes beyond 30 days, excluding studies that only described functional outcome and mortality at discharge. Also, studies that included patients with various large vessel occlusions without explicitly reporting the clinical outcome of the patients with ICA occlusions were excluded. The ICA occlusion had to be confirmed by at least one imaging modality such as carotid ultrasound, digital subtraction

Correspondence to Dr Henk A Marquering, Departments of Radiology and Biomedical Engineering and Physics, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; h.a.marquering@amc.uva.nl

Received 11 October 2013
Revised 5 December 2013
Accepted 12 December 2013
Published Online First
2 January 2014
angiography (DSA), MR angiography (MRA) or CT angiography (CTA). This criterion did not exclude any articles. One article was excluded because it did not specify which endovascular treatment was given. Three studies used the data of the MERCI and Multi MERCI trials.8–10 Two of these were excluded to prevent double usage of the same data sets. Figure 1 shows a flow diagram presenting the search and inclusion and exclusion of publications identified in the literature review.

The search resulted in 32 articles. Treatment modality was recorded and, if possible, the patient groups were categorized according to ICA occlusion site and treatment. The outcome measures were success of recanalization, sICH, favorable outcome and death rates.

Twenty-six studies used either the Thrombolysis In Myocardial Infarction (TIMI) or Thrombolysis in Cerebrovascular Infarction (TICI) score to describe the success of recanalization. One study used the Mori score,11 which is comparable to the TIMI and Thrombolysis in Cerebrovascular Infarction (TICI) scores. In the other five studies, definitions based on the judgment of the interventional radiologist such as ‘successful’ were used.12–16 A favorable long-term functional outcome was defined as a mRS score of 0–2 or a Barthel Index of >90, assessed 1 month or later after treatment. Only one study used a combination of the mRS and National Institute of Health Stroke Scale (NIHSS) scores.17 Most studies defined sICH as an intracranial hemorrhage with a worsening of 4 points on the NIHSS scale.18 In some studies, hemorrhages with clinical symptoms or type II parenchymal hemorrhages were reported. These were considered sICHS as well in this review.

If data were missing from an article, we searched for online supplementary tables. If the missing information was not retrievable but did not concern one of the two primary outcomes (mortality and long-term functional outcome), this was noted and the study was included. If one of the two primary outcome measures was missing, the study was excluded. In two studies,19 20 the information was incomplete or unclear. In these cases, we tried to contact the corresponding authors by email. In one study,19 the data were retrieved in this way. The second study was not excluded but the inconsistency is noted in table 1.

![Figure 1](image)

Figure 1 Flowchart showing screening and selection of studies during the search process (n denotes the number of excluded studies). IA, intra-arterial; ICA, internal carotid artery.

After collecting the data, we grouped the results by occlusion sites, creating three populations. Population 1 consisted of patients with an intracranial ICA occlusion, patients in population 2 had an extracranial ICA occlusion and patients in the third population had a tandem occlusion (a simultaneous occlusion of the extracranial and ipsilateral intracranial ICA). We did not discriminate for prior IVT treatment. For patients with an intracranial ICA occlusion (population 1), the treatment options were IAT with or without MCD and mechanical thrombectomy (MT). MT included angioplasty, aspiration thrombectomy (Penumbra) and retrieval with a MERCI device or stent retrievers (Solitaire, Trevo, Revive). For patients with an extracranial ICA occlusion (population 2), the treatment possibilities consisted of IAT with or without MCD and stenting with or without aspiration. For patients with a tandem occlusion (population 3), we analyzed recanalization rates of IAT and MT in intracranial occlusions and of IAT and stenting in extracranial occlusions. Furthermore, we analyzed clinical outcomes for patients with a tandem occlusion. We grouped together studies with similar treatment of extracranial and intracranial occlusion, resulting in four groups: (1) IAT treatment of both extracranial and intracranial occlusions; (2) stenting of the extracranial occlusion and IAT of the intracranial occlusion; (3) stenting of the intracranial occlusion and treatment with stent retrievers of the intracranial occlusion; and (4) stenting of the extracranial occlusion and a combination of multiple treatments for the intracranial occlusion.

SPSS Statistics V21 was used to perform statistical analysis. Because the outcome measures (recanalization, mortality, sICH and favorable outcome) were dichotomous, we used the χ² test to calculate the significance levels. A level of p<0.05 was considered significant. For the comparison of the different tandem occlusion groups, the numbers were too low to use the χ² test so the Fisher test was used instead.

RESULTS

We included 32 studies with a total of 1107 patients with a mean±SD age of 65±4.9 years. The overall recanalization rate was 70% (771), the sICH rate was 9% (97), the death rate was 33% (365) and the favorable outcome rate was 29% (321). Table 1 gives an overview of the collected data presented in chronological order.

Intracranial occlusions (population 1)

We included six studies4 12 14 20 22 31 totaling 95 patients with an intracranial occlusion treated by IAT (see online supplementary table S1) and eight studies17 20 26 30 32 36 38 40 with 115 patients with an intracranial occlusion treated by MT (see online supplementary table S1). Overall outcome rates were 55% recanalization, 12% sICH, 34% mortality and 25% favorable outcome (see online supplementary table S2). Comparison between treatments showed a higher recanalization rate (69% vs 38%, p<0.001) and favorable outcome rate (34% vs 14%, p<0.001) and a lower death rate (29% vs 40%, p=0.085) for patients with MT. The sICH rates were similar for both treatments (12.2% vs 11.7%, p=0.085; figure 2).

Extracranial occlusions (population 2)

Two studies13 23 with a total of 27 patients described results of IAT for extracranial ICA occlusions (see online supplementary table S3). The stenting group comprised four studies15 16 24 33 and a total of 38 patients (see online supplementary table S3). Overall outcome rates were 71% recanalization, 2% sICH, 28% mortality and 46% favorable outcome (see online
<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>Mean age</th>
<th>Mean NIHSS at intake</th>
<th>Mean TT (min)</th>
<th>Treatment</th>
<th>Rec (%)</th>
<th>Definition rec</th>
<th>sICH (%)</th>
<th>Mortality (%)</th>
<th>Favorable outcome (%)</th>
<th>Definition of favorable outcome</th>
<th>Occlusion site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urbach et al[^12]</td>
<td>12</td>
<td>51</td>
<td>NR</td>
<td>190</td>
<td>IAT (UK)</td>
<td>4 (33)</td>
<td>Good/moderate</td>
<td>1 (8)</td>
<td>4 (33)</td>
<td>4 (33)</td>
<td>BI &gt;90 at 3 months</td>
<td>T</td>
</tr>
<tr>
<td>Endo et al[^13]</td>
<td>16</td>
<td>68</td>
<td>NR (&lt;24)</td>
<td>NR (25-360)</td>
<td>IAT (UK)/rtPA</td>
<td>3 (19)</td>
<td>Successful</td>
<td>1 (6)</td>
<td>10 (62.5)</td>
<td>0 (0)</td>
<td>mRS 0–2 at 1 months</td>
<td>EC</td>
</tr>
<tr>
<td>Zaidat et al[^14]</td>
<td>5</td>
<td>69</td>
<td>15*</td>
<td>143</td>
<td>IAT (UK)+IVT (rtPA)</td>
<td>4 (80)</td>
<td>Partial/complete</td>
<td>1 (20)</td>
<td>1 (20)</td>
<td>3 (60)</td>
<td>mRS 0–2 at 3 months</td>
<td>T, L</td>
</tr>
<tr>
<td>Arnol et al[^15]</td>
<td>13</td>
<td>60</td>
<td>19*</td>
<td>237</td>
<td>IAT (UK)+angioplasty, stent</td>
<td>15 (62.5)</td>
<td>TIMI 2/3</td>
<td>1 (4)</td>
<td>10 (42)</td>
<td>4 (17)</td>
<td>mRS 0–2 at 3 months</td>
<td>T</td>
</tr>
<tr>
<td>Eckert et al[^16]</td>
<td>43</td>
<td>55</td>
<td>NR (&lt;9)</td>
<td>13 (30)</td>
<td>IAT (UK)/rtPA/rtPA+hps-plasminogen</td>
<td>15 (35)</td>
<td>TIMI 2/3</td>
<td>6 (14)</td>
<td></td>
<td>Bi &gt;90 at 3 months</td>
<td>T</td>
<td></td>
</tr>
<tr>
<td>Sorimachi et al[^17]</td>
<td>11</td>
<td>71</td>
<td>23</td>
<td>212</td>
<td>IAT (UK)+MCD</td>
<td>10 (91)</td>
<td>Opened</td>
<td>0 (0)</td>
<td>1 (9)</td>
<td>4 (36)</td>
<td>mRS 0–2 at 3 months</td>
<td>EC</td>
</tr>
<tr>
<td>Jovin et al[^18]</td>
<td>15</td>
<td>59</td>
<td>16</td>
<td>300</td>
<td>Stent+angioplasty+8 IVT (rtPA)</td>
<td>15 (100)</td>
<td>Successful</td>
<td>3 (20)</td>
<td>5 (33)</td>
<td>mRS 0–2 at 1 months</td>
<td>5 E, 5 T</td>
<td></td>
</tr>
<tr>
<td>Nedeltchev et al[^19]</td>
<td>25</td>
<td>59</td>
<td>12*</td>
<td>169</td>
<td>Stent+IAT</td>
<td>21 (84)</td>
<td>TIMI 2/3</td>
<td>2 (8)</td>
<td>14 (56)</td>
<td>mRS 0–2 at 1 months</td>
<td>21 E, 5 T</td>
<td></td>
</tr>
<tr>
<td>Mori et al[^20]</td>
<td>14</td>
<td>76</td>
<td>20</td>
<td>183</td>
<td>Stent retrieval+aspiration</td>
<td>7 (50)</td>
<td>TIMI 2/3</td>
<td>2 (14)</td>
<td>6 (43)</td>
<td>mRS 0–2 at 3 months</td>
<td>6 E, 8 IC</td>
<td></td>
</tr>
<tr>
<td>Suh et al[^21]</td>
<td>30</td>
<td>66</td>
<td>15*</td>
<td>161</td>
<td>16 IAT, 9 IAT+stenting/thrombectomy, 3 IAT+angioplasty, stent only</td>
<td>14 (47)</td>
<td>TIMI 2/3</td>
<td>6 (20)</td>
<td>11 (37)</td>
<td>mRS 0–2 at 1 year</td>
<td>26 E, 7 IC</td>
<td></td>
</tr>
<tr>
<td>Arnold et al[^22]</td>
<td>43</td>
<td>60</td>
<td>NR</td>
<td>257</td>
<td>IAT (UK)</td>
<td>26 (58)</td>
<td>TIMI 2/3</td>
<td>4 (9)</td>
<td>16 (37)</td>
<td>10 (23)</td>
<td>mRS 0–2 at 3 months</td>
<td>30 T, 13 E</td>
</tr>
<tr>
<td>Miyamoto et al[^23]</td>
<td>10</td>
<td>77</td>
<td>11</td>
<td>330</td>
<td>Stent+angioplasty+IVT (UK)+for intracranial IAT (UK)</td>
<td>10 (100)</td>
<td>Complete</td>
<td>0 (0)</td>
<td>1 (10)</td>
<td>6 (60)</td>
<td>mRS 0–2 at 3 months</td>
<td>5 E, 5 T</td>
</tr>
<tr>
<td>Kim et al[^24]</td>
<td>10</td>
<td>60</td>
<td>13</td>
<td>289</td>
<td>IAT (UK)</td>
<td>6 (60)</td>
<td>TIMI 2/3</td>
<td>1 (10)</td>
<td>0 (0)</td>
<td>5 (50)</td>
<td>mRS 0–2 at 3 months</td>
<td>Tandem</td>
</tr>
<tr>
<td>Lin et al[^25]</td>
<td>40</td>
<td>68</td>
<td>17*</td>
<td>343</td>
<td>IAT (rtPA/UK)+mechanical (MERCRI retrieval/angioplasty/stent)</td>
<td>26 (65)</td>
<td>TIMI 2/3</td>
<td>3 (7.5)</td>
<td>14 (35)</td>
<td>17 (23)</td>
<td>mRS 0–2 at 3 months</td>
<td>61 T, 14 L</td>
</tr>
<tr>
<td>18 71 18*</td>
<td>374</td>
<td>Mechanical (MERCRI retrieval/ angioplasty/stent)</td>
<td>6 (33)</td>
<td>TIMI 2/3</td>
<td>3 (17)</td>
<td>8 (44)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 63 17*</td>
<td>338</td>
<td>IAT (rtPA/UK)</td>
<td>3 (18)</td>
<td>TIMI 2/3</td>
<td>2 (12)</td>
<td>6 (35)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 69 18</td>
<td>246</td>
<td>IAT (UK)+IVT (rtPA)/MERCRI retriever/ MCD/angioplasty/stent</td>
<td>12 (75)</td>
<td>10 (60)</td>
<td>2 (2)</td>
<td>5 (31)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shi et al[^26]</td>
<td>18</td>
<td>68</td>
<td>20</td>
<td>258</td>
<td>Merci retriever+IVT (rtPA)±IAT (rtPA/ UK/tenectepase)</td>
<td>12 (67)</td>
<td>TIMI 2/3</td>
<td>2 (11)</td>
<td>6 (33)</td>
<td>5 (28)</td>
<td>mRS 0–2 at 3 months</td>
<td>1 E, 17 T</td>
</tr>
<tr>
<td>81 68 20</td>
<td>56</td>
<td>Merci retriever/IAT (rtPA/UK/ tenectepase)</td>
<td>50 (62)</td>
<td>TIMI 2/3</td>
<td>9 (11)</td>
<td>41 (51)</td>
<td>23 (28)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miteff et al[^27]</td>
<td>6</td>
<td>70</td>
<td>20</td>
<td>389</td>
<td>Stent retrieval</td>
<td>6 (100)</td>
<td>TIMI 2/3</td>
<td>0 (0)</td>
<td>3 (50)</td>
<td>mRS 0–2 at 3 months</td>
<td>3 T, 2 T, 2 tandem, 1 Tandem</td>
<td></td>
</tr>
<tr>
<td>5 65 16</td>
<td>313</td>
<td>Stent retrieval+Penumbra/MERCRI/IAT (UK)</td>
<td>4 (80)</td>
<td>TIMI 2/3</td>
<td>1 (20)</td>
<td>3 (60)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costalat et al[^28]</td>
<td>14</td>
<td>70</td>
<td>15</td>
<td>243</td>
<td>Stent retriever+IVT (warfarin)</td>
<td>10 (71)</td>
<td>TICI 3</td>
<td>2 (14)</td>
<td>6 (43)</td>
<td>mRS 0–2 at 3 months</td>
<td>T/L</td>
<td></td>
</tr>
<tr>
<td>Watanabe et al[^29]</td>
<td>10</td>
<td>81</td>
<td>18*</td>
<td>148</td>
<td>IAT (UK)/MCD</td>
<td>5 (50)</td>
<td>TICI 2/3</td>
<td>2 (20)</td>
<td>4 (40)</td>
<td>1 (10)</td>
<td>mRS 0–2 at 3 months</td>
<td>T</td>
</tr>
<tr>
<td>Fesli et al[^30]</td>
<td>14</td>
<td>59</td>
<td>19*</td>
<td>252</td>
<td>Aspiration+other mechanical</td>
<td>11 (79)</td>
<td>TIMI 2/3</td>
<td>7 (50)</td>
<td>6 (43)</td>
<td>3 (21)</td>
<td>mRS 0–2 at 3 months</td>
<td>T</td>
</tr>
<tr>
<td>Poppanagiotou et al[^31]</td>
<td>22 65</td>
<td>17</td>
<td>246</td>
<td>Stents+angioplasty+IVT (rtPA)</td>
<td>21 (95)</td>
<td>TIMI 2/3</td>
<td>4 (18)</td>
<td>3 (14)</td>
<td>9 (41)</td>
<td>mRS 0–2 at 3 months</td>
<td>4 E, 18 Tandem</td>
<td></td>
</tr>
<tr>
<td>Malik et al[^32]</td>
<td>77</td>
<td>63</td>
<td>15</td>
<td>433</td>
<td>Stent+angioplasty</td>
<td>58 (75)</td>
<td>TIMI 2/3</td>
<td>8 (10)</td>
<td>19 (25)</td>
<td>32 (42)</td>
<td>mRS 0–2 at 3 months</td>
<td>Tandem</td>
</tr>
<tr>
<td>Hauck et al[^33]</td>
<td>22</td>
<td>65</td>
<td>14</td>
<td>NR</td>
<td>Stent+IVT (rtPA)</td>
<td>17 (77)</td>
<td>TIMI 2/3</td>
<td>0 (0)</td>
<td>7 (32)</td>
<td>11 (50)</td>
<td>mRS 0–2 at 3 months</td>
<td>EC</td>
</tr>
<tr>
<td>Pagola et al[^34]</td>
<td>41</td>
<td>70</td>
<td>19</td>
<td>290</td>
<td>IAT (rtPA)/MCD</td>
<td>25 (61)</td>
<td>TICI 2/3</td>
<td>4 (10)</td>
<td>18 (44)</td>
<td>5 (12)</td>
<td>mRS 0–2 at 3 months</td>
<td>NR</td>
</tr>
<tr>
<td>Study</td>
<td>n</td>
<td>Mean age</td>
<td>Mean NIHSS at intake</td>
<td>Mean TT (min)</td>
<td>Treatment</td>
<td>Rec (%)</td>
<td>Definition rec</td>
<td>sICH (%)</td>
<td>Mortality (%)</td>
<td>Favorable outcome (%)</td>
<td>Definition of favorable outcome</td>
<td>Occlusion site</td>
</tr>
<tr>
<td>----------</td>
<td>-----</td>
<td>----------</td>
<td>----------------------</td>
<td>---------------</td>
<td>---------------------------------------------------------------------------</td>
<td>---------</td>
<td>---------------</td>
<td>----------</td>
<td>---------------</td>
<td>----------------------</td>
<td>--------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Hwang et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>2</td>
<td>71</td>
<td>21</td>
<td>330</td>
<td>Combined</td>
<td>2 (100)</td>
<td>TICI 2/3</td>
<td>0 (0)</td>
<td>1 (50)</td>
<td>1 (50)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>65</td>
<td>18</td>
<td>127</td>
<td>Aspiration</td>
<td>17 (85)</td>
<td>TICI 2/3</td>
<td>3 (15)</td>
<td>0 (0)</td>
<td>9 (45)</td>
<td>mRS 0–2 at 3 months</td>
<td>T/L</td>
</tr>
<tr>
<td>Hwang et al&lt;sup&gt;36&lt;/sup&gt;</td>
<td>19</td>
<td>66</td>
<td>16</td>
<td>78</td>
<td>MCD±8 IAT (UK)</td>
<td>6 (32)</td>
<td>TICI 2/3</td>
<td>2 (10.5)</td>
<td>2 (10.5)</td>
<td>3 (16)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>72</td>
<td>62</td>
<td>17</td>
<td>280</td>
<td>Mechanical (angioplasty/MCD/stent retrieval/stents/aspiration)±IVT (rtPA)</td>
<td>64 (82)</td>
<td>TICI 2/3</td>
<td>5 (6)</td>
<td>24 (31)</td>
<td>23 (29)</td>
<td>mRS 0–2 at 3 months</td>
<td>107 T, 76 tandem, 18 EC, 5 IC</td>
</tr>
<tr>
<td>Fischer et al&lt;sup&gt;37&lt;/sup&gt;</td>
<td>32</td>
<td>62</td>
<td>17</td>
<td>19</td>
<td>IAT (UK)±IVT (rtPA)</td>
<td>15 (47)</td>
<td>TIMI 2/3</td>
<td>1 (3)</td>
<td>10 (31)</td>
<td>5 (16)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td>80</td>
<td>66</td>
<td>16</td>
<td>91</td>
<td>Stent retriever±IAT (UK)/MCD/angioplasty/aspiration±IVT (rtPA)</td>
<td>78 (86)</td>
<td>TIMI 2/3</td>
<td>6 (7)</td>
<td>26 (29)</td>
<td>26 (29)</td>
<td>mRS 0–2 at 3 months</td>
<td>IC</td>
</tr>
<tr>
<td>Yoon et al&lt;sup&gt;38&lt;/sup&gt;</td>
<td>26</td>
<td>73</td>
<td>13</td>
<td>240</td>
<td>Stent retriever±IAT (UK)/MCD/angioplasty/aspiration±IVT (rtPA)</td>
<td>20 (77)</td>
<td>TICI 2b/3</td>
<td>0 (0)</td>
<td>10 (38)</td>
<td>10 (38)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
</tr>
<tr>
<td>Mpotsaris et al&lt;sup&gt;39&lt;/sup&gt;</td>
<td>41</td>
<td>62</td>
<td>16</td>
<td>NR</td>
<td>Stent retriever±stent (Wallstent)±34 IVT (rtPA)</td>
<td>35 (85)</td>
<td>TIMI 2/3</td>
<td>3 (7)</td>
<td>15 (37)</td>
<td>15 (37)</td>
<td>mRS 0–2 at 3 months</td>
<td>Tandem</td>
</tr>
<tr>
<td>Lee et al&lt;sup&gt;40&lt;/sup&gt;</td>
<td>10</td>
<td>69</td>
<td>18</td>
<td>NR</td>
<td>Stent retriever+aspiration+IVT (rtPA)±stent</td>
<td>6 (60)</td>
<td>TICI 2/3</td>
<td>0 (0)</td>
<td>4 (40)</td>
<td>0 (0)</td>
<td>mRS 0–2 at 3 months</td>
<td>T/L</td>
</tr>
<tr>
<td>Matsubara et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>16</td>
<td>66</td>
<td>16</td>
<td>NR</td>
<td>IAT (UK)±7 IVT (tPA)</td>
<td>12 (75)</td>
<td>TICI 2/3</td>
<td>1 (6)</td>
<td>8 (50)</td>
<td>1 (6)</td>
<td>mRS 0–2 at 3 months</td>
<td></td>
</tr>
<tr>
<td>Dalyai et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>14</td>
<td>68</td>
<td>16</td>
<td>175</td>
<td>Stent/angioplasty/aspiration±IVT (tPA)</td>
<td>14 (100)</td>
<td>TICI 2/3</td>
<td>1 (7)</td>
<td>4 (29)</td>
<td>4 (29)</td>
<td>mRS 0–2 at 3 months</td>
<td>10 tandem, 6 EC</td>
</tr>
<tr>
<td>Kwak et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>35</td>
<td>65</td>
<td>12*</td>
<td>450</td>
<td>Stent+angioplasty±IVT (rtPA)</td>
<td>16 (94)</td>
<td>‘Successful’</td>
<td>3 (18)</td>
<td>9 (53)</td>
<td>9 (53)</td>
<td>mRS 0–2 at 3 months</td>
<td>6 EC, 11 tandem</td>
</tr>
<tr>
<td>Kwak et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>80</td>
<td>65</td>
<td>12</td>
<td>450</td>
<td>Stent+angioplasty±8 IV rtPA</td>
<td>35 (100)</td>
<td>TICI 2/3</td>
<td>1 (3)</td>
<td>22 (63)</td>
<td>4 (11)</td>
<td>mRS 0–2 at 3 months</td>
<td>T/L</td>
</tr>
</tbody>
</table>

Data in italics are extrapolated.

*Favorable outcome rates were only reported for entire patient group, not for each treatment.

† Originally there were 16 patients, but in two cases the occlusion was caused by a dissection of the ICA. They were excluded and the reported percentages were used for the 14 remaining cases.

ACA, anterior cerebral artery; BI, Barthel Index; CEA, carotid endarterectomy; EC, extracranial; IAT, intra-arterial thrombolysis; IC, intracranial; ICA, internal carotid artery; L, l-occlusion; MCA, medial cerebral artery; MCD, mechanical clot disruption; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; NR, not retrievable proximal; PTA, percutaneous transluminal angioplasty; rec, recanalization; rtPA, recombinant tissue plasminogen activator; sICH, symptomatic intracranial hemorrhage; T, T-occlusion; thrombus extending in both the ACA and MCA; thrombus extending in either the ACA or MCA; TICI, Thrombolysis In Cerebral Infarction; TIMI, Thrombolysis In Myocardial Infarction; TT, time to treatment; UK, urokinase.
supplementary table S4). The pooled outcome of the treatment results in the extracranial occlusion population is shown in figure 3. Recanalization and favorable outcome rates were significantly higher for stenting than for thrombolysis (87% vs 48% (p=0.001) and 68% vs 15% (p<0.001), respectively). Mortality was higher for IAT than for stenting, although the difference was only marginally significant (41% vs 18%, p=0.048). The sICH rates were not significantly different (4% for IAT, 0% for stenting, p=0.23).

**Tandem occlusions (population 3)**

Ten studies with tandem ICA occlusions were included (see online supplementary table S5). Figure 4 shows an overview of the treatment results. Overall outcome rates were 16% sICH, 45% mortality and 43% favorable outcome. We included three studies\(^\text{\textsuperscript{15}}\) \(^\text{\textsuperscript{24}}\) \(^\text{\textsuperscript{29}}\) with intracranial IAT, comprising a total of 25 patients. Of this population, 15 patients (60%) showed sufficient recanalization. Two studies\(^\text{\textsuperscript{33}}\) \(^\text{\textsuperscript{39}}\) were included that treated the intracranial occlusion with MT. Of this population of 59

Figure 2  Intra-arterial treatments for intracranial occlusions. \(^*\)p<0.05. sICH, symptomatic intracranial hemorrhage.

Figure 3  Comparison of outcomes for IAT and stenting in extracranial occlusions. \(^*\)p<0.05. IAT, intra-arterial thrombolysis; sICH, symptomatic intracranial hemorrhage.
patients, 46 showed recanalization (78%). This difference in recanalization between IAT and MT was not statistically significant (p=0.09).

Two studies\textsuperscript{22,29} with a total of 18 patients described IAT of an extracranial ICA occlusion. Eleven patients (61%) recanalized. Seven studies\textsuperscript{15,16,24,33,34,39,42} with 197 patients described stenting of the extracranial ICA occlusion. Of these, 196 (99%) recanalized resulting in a statistically significant difference in recanalization rate compared with patients treated with IAT of the extracranial ICA (p<0.001).

In the comparison of the four groups based on intracranial and extracranial treatment, the only statistically significant differences were found for death rates in favor of the combined IAT treatment for both extracranial and intracranial treatment compared with patients with any mechanical treatment of the intracranial occlusion (see online supplementary table S6). These differences were 0% vs 34% (p=0.002) for the comparison of IAT for both occlusions with stenting for the extracranial occlusion, and 0% vs 33% (p=0.001) for the comparison of IAT for both occlusions with stenting for the extracranial occlusion and a combination of IAT and mechanical methods for the intracranial occlusion.

DISCUSSION

The results of this review suggest that mechanical treatment methods—particularly stenting in extracranial occlusions—achieve better recanalization, higher favorable outcome rates and lower death rates than IAT only in patients with AIS resulting from an occlusion of the ICA.

This study is one of the first to review the IA treatment of AIS due to ICA occlusion. Our review included nine extra studies from 2013 compared with a previous review,\textsuperscript{7} which included articles published only until November 2011, resulting in 406 more patients. Moreover, to our knowledge, this is the first review to differentiate between IA treatment modalities and occlusion site.

For intracranial ICA occlusions, MT was superior to IAT. A possible explanation could be that an occlusion of the ICA is associated with a higher clot burden which makes it more likely for mechanical therapies to achieve recanalization success. Additionally, the mechanical therapies are faster, which may influence the clinical outcome. For extracranial ICA occlusions, stenting was superior to IAT. This might be because the vast majority of extracranial occlusions relate to local severe atherosclerotic plaque. Greater and immediate flow restoration from stenting improves distal perfusion and may deliver endogenous fibrinolytics.

Depending on the configuration of the circle of Willis and associated hemodynamic compromise, acute occlusion of the extracranial ICA may or may not cause symptoms and, as such, patients with an occlusion of the extracranial artery may differ from those with AIS due to an intracranial occlusion. However, extracranial occlusions are treated in the acute setting by some centers. We therefore decided to include patients with acute stroke with purely extracranial ICA occlusions.

Our results are in line with the findings of Mokin et al\textsuperscript{7} who found a favorable outcome rate of 33.6% (vs 29.0% in this review) and a death rate of 32.0% (vs 33.0% in this review) for IA treatment. Mokin et al also pooled their results by occlusion site: cervical ICA occlusions (193 patients) and carotid T-occlusions. In patients with a cervical ICA occlusion they found an overall favorable outcome rate of 43.5%, which is in line with the favorable outcome rate of 46% in the extracranial population in this review. For carotid T-occlusions, Mokin et al reported an overall favorable outcome rate of 28.5% in the IA treated group, which is also comparable to the mean favorable outcome rate of 24.8% in our intracranial occlusion population.

A major limitation in this field of research is the lack of large randomized controlled trials (RCTs). Most of our included studies were retrospective so they were prone to selection and other biases. Only a few studies were prospective. In addition, we used both single-center and multicenter studies. This heterogeneity may cause differences in outcome attributable to other factors such as different treatment protocols. Another limitation...
of our included studies is the fact that the choice of the material and techniques used for MT was not prescribed by the trial protocol, but left to the treating interventional radiologist. Moreover, devices are constantly developed and improved over time. Recent RCTs such as the TREVO 2 and SWIFT trial have shown that the recanalization rates and outcomes of stent retrievers are better than those of MERCI retrievers. Therefore, it can be expected that the older studies that used MERCI devices may have had worse recanalization rates and outcomes, influencing the total results of the analysis of the intracranial occlusion group. Finally, another aspect of heterogeneity lies in the fact that the definition of successful recanalization varied between studies. This may have caused falsely low or high recanalization rates.

In our review we limited our evaluation to endovascular treatment modality and its relationship with outcome. Other factors such as the use of IVT and clinical (age, stroke severity, time to treatment, time to recanalization) and imaging parameters (pretreatment ASPECTS, infarct core volume and collateral flow) were not evaluated. By including a large number of studies in our review, the effect of these parameters is probably equally distributed. Nevertheless, the pooling resulted in a few small groups where these other parameters may have had an important impact on clinical outcome.

For the analysis of mortality, favorable outcome and sICH rates in the population with tandem occlusions, the number of the patients per group was low. Only a statistically significant difference was found in the death rate in favor of IAT. However, only two studies were used in this pooling and this difference may also be caused by different patient selection. For example, patients in the IAT/IAT group were, on average, 3–4 years younger than those of the groups with a significantly higher mortality.

Finally, not all studies reported data on occlusion sites or treatment results of different occlusion sites. Those studies could not be included in the pooling of our results. As a result, some of the groups were rather small. This may have biased the pooled outcomes.

We believe that subgroup analysis of patients with ICA occlusion from the recent completed and ongoing trials will improve the evaluation of different IA treatment options.

CONCLUSIONS

Our review suggests that, in patients with AIS due to ICA occlusion, mechanical approaches are associated with higher recanalization rates and improved functional outcomes compared with IAT.

Contributors CBLMM and HAM contributed to the study design and methodology. MK contributed to the data collection, data interpretation and statistical analysis. HAM, OAB, CBLMM contributed to the data interpretation. HAM contributed to the statistical analysis. MK, HAM, OAB and CBLMM contributed to the Introduction, Methods, Results and Discussion sections, both in writing and revising the manuscript. All authors approved the final version to be published and all authors agreed to be accountable for all aspects of the work.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Any unpublished data from this study are available through contacting the corresponding author. The authors will be happy to supply any information needed. This includes the PubMed search, the data extraction document, the data calculation Excel document, SPSS files and the Fisher test Excel document.

REFERENCES


Intra-arterial treatment of patients with acute ischemic stroke and internal carotid artery occlusion: a literature review

Manon Kappelhof, Henk A Marquering, Olvert A Berkhemer and Charles B L M Majoie

*J NeuroIntervent Surg* 2015 7: 8-15 originally published online January 2, 2014
doi: 10.1136/neurintsurg-2013-011004

Updated information and services can be found at:
http://jnis.bmj.com/content/7/1/8

**Supplementary Material**
Supplementary material can be found at:
http://jnis.bmj.com/content/suppl/2014/01/02/neurintsurg-2013-011004.DC1

**References**
This article cites 44 articles, 23 of which you can access for free at:
http://jnis.bmj.com/content/7/1/8#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections
Ischemic stroke (413)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/